Clinical and research tests for C2750850 - Genetic Testing Registry (GTR) - NCBI

Warning: The NCBI web site requires JavaScript to function. more...

<< First < Prev

Page 2 of 6

Results: 21 to 40 of 109

Tests names and labs	Conditions	Genes, analytes, and microbes	Methods
Variant Resolution Test for Penn Cancer Grant Panel (+RNAinsight®) Ambry Genetics United States	79	18	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Penn Cancer Grant Panel Ambry Genetics United States	79	80	D Deletion/duplication analysis C Sequence analysis of the entire coding region
MarrowZoom Johns Hopkins Genomics DNA Diagnostic Laboratory Johns Hopkins University, School of Medicine United States	249	155	C Sequence analysis of the entire coding region
Inherited Bone Marrow Failure Panel PreventionGenetics, part of Exact Sciences United States	266	186	D Deletion/duplication analysis C Sequence analysis of the entire coding region T Targeted variant analysis
BRCANext-Expanded™ Ambry Genetics United States	35	20	D Deletion/duplication analysis C Sequence analysis of the entire coding region
BRCANext™ Ambry Genetics United States	35	18	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Glioma susceptibility 1, 137800, Autosomal dominant, Somatic mutation (Glial tumor) (MLPA) Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey	1	1	D Deletion/duplication analysis
Glioma, susceptibility to, somatic, 137800; GLM1 (Glial tumor) (Codon 132 and IDH2 172 mutations) (IDH1 gene) (Sequence Analysis) (Postnatal) Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey	1	1	E Sequence analysis of select exons
Glioma susceptibility 1, 137800, Autosomal dominant, Somatic mutation (Glial tumor) (TP53 gene) (Sequence Analysis-All Coding Exons) (Postnatal) Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey	1	1	C Sequence analysis of the entire coding region
Ovarian cancer, somatic (ERBB2-HER2) (FISH) Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey	1	1	F Fluorescence in situ hybridization (FISH)
Medulloblastoma Panel PreventionGenetics, part of Exact Sciences United States	21	9	D Deletion/duplication analysis C Sequence analysis of the entire coding region T Targeted variant analysis
Wilms Tumor Panel PreventionGenetics, part of Exact Sciences United States	48	28	D Deletion/duplication analysis C Sequence analysis of the entire coding region T Targeted variant analysis
Variant Resolution Test for CancerNext® (+RNAinsight®) Ambry Genetics United States	55	34	D Deletion/duplication analysis R RNA analysis C Sequence analysis of the entire coding region
Invitae Genetic Health Screen Labcorp Genetics (formerly Invitae) LabCorp United States	409	164	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Invitae Cancer Screen Labcorp Genetics (formerly Invitae) LabCorp United States	160	62	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Invitae 78 Gene Actionable Disorders Panel Labcorp Genetics (formerly Invitae) LabCorp United States	220	75	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Variant Resolution Test for CustomNext-Cancer® (+RNAinsight®) Ambry Genetics United States	146	18	D Deletion/duplication analysis R RNA analysis C Sequence analysis of the entire coding region
Variant Resolution Test for MelanomaNext® (+RNAinsight®) Ambry Genetics United States	40	3	D Deletion/duplication analysis R RNA analysis C Sequence analysis of the entire coding region
Variant Resolution Test for BrainTumorNext® (+RNAinsight®) Ambry Genetics United States	71	8	D Deletion/duplication analysis R RNA analysis C Sequence analysis of the entire coding region
Variant Resolution Test for ProstateNext® (+RNAinsight®) Ambry Genetics United States	40	11	D Deletion/duplication analysis R RNA analysis C Sequence analysis of the entire coding region

<< First < Prev

Page 2 of 6

Results: 21 to 40 of 109

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.